Multikinase Inhibitor Treatment Patterns for Advanced Thyroid Cancer in Japan: An Administrative Claims Database Study

Multikinase Inhibitor Treatment Patterns for Advanced Thyroid Cancer in Japan: An Administrative Claims Database Study

Abstract Background The multikinase inhibitors (MKIs) sorafenib, lenvatinib, and vandetanib are approved for advanced thyroid cancer (TC) in Japan. How sequential treatment with MKIs is conducted in Japanese clinical practice is unknown. Methods This retrospective observational cohort study used a J...

Full description

Bibliographic Details
Main Authors:	Chie Masaki, Kiminori Sugino, Yoshinori Tanizawa, Kenichi Nakamura, Yui Okada, Zhihong Cai, Takahiro Okamoto
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2022-12-01
Series:	Drugs - Real World Outcomes
Online Access:	https://doi.org/10.1007/s40801-022-00346-y

Similar Items

Emerging role of multikinase inhibitors for refractory thyroid cancer
by: Perez CA, et al.
Published: (2012-08-01)

Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database.
by: Eiji Shinozaki, et al.
Published: (2021-01-01)

Side skin reactions of multikinase inhibitors in treatment of thyroid cancer
by: F. S. Sevryukov, et al.
Published: (2021-01-01)

Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
by: Carles Zafón, et al.
Published: (2022-10-01)

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
by: Stjepanovic N, et al.
Published: (2014-04-01)

Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma
by: Carla Fernanda Nava, et al.
Published: (2019-10-01)

Association between osteoarthritis and cardiovascular disease in elderly in Japan: an administrative claims database analysis
by: Shuko Nojiri, et al.
Published: (2024-03-01)

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer
by: Tiziana Feola, et al.
Published: (2021-07-01)

Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer
by: Neus Basté Rotllan
Published: (2022-10-01)

The role of multikinase inhibitors target therapy in radioiodine-resistant differentiated thyroid cancer
by: P O Rumyantsev
Published: (2015-06-01)

Real‐world burden and treatment of chronic rhinosinusitis in Japan: A retrospective claims database analysis
by: Mamoru Yoshikawa, et al.
Published: (2023-04-01)

Hypnotic prescription trends and patterns for the treatment of insomnia in Japan: analysis of a nationwide Japanese claims database
by: Shoki Okuda, et al.
Published: (2023-04-01)

Rare complications of multikinase inhibitor treatment
by: Fabián Pitoia, et al.

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
by: Urbano Anido Herranz
Published: (2022-10-01)

Prescription pattern of anti-Parkinson's disease drugs in Japan based on a nationwide medical claims database
by: Masahiko Suzuki, et al.
Published: (2020-09-01)

What Characterizes Education in Women’s Universities in Japan? An Analysis of Diploma Policies
by: Chie Sugino
Published: (2023-10-01)

Combination of targeted multikinase inhibitor and radioiodine: a new strategy of treatment for advanced differentiated thyroid carcinoma
by: LIU Wei
Published: (2023-11-01)

Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine‐refractory differentiated thyroid cancer
by: Miguel‐Ángel Berciano‐Guerrero
Published: (2022-10-01)

Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database
by: Izumi Kawachi, et al.
Published: (2019-12-01)

Daily Management of Patients on Multikinase Inhibitors’ Treatment
by: Carla Colombo, et al.
Published: (2022-07-01)

Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database.
by: Hiroshi Handa, et al.
Published: (2023-01-01)

Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database
by: Hiroshi Handa, et al.
Published: (2023-01-01)

Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive‐resistant differentiated thyroid cancer
by: Marcel Sambo
Published: (2022-10-01)

Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory‐differentiated thyroid cancer
by: Paula Jimenez‐Fonseca
Published: (2022-10-01)

Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis
by: Katsuyoshi Matsuoka, et al.
Published: (2023-01-01)

Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma
by: Haruhiko Yamazaki, et al.
Published: (2023-02-01)

Sequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma
by: Chiara Paglino, et al.
Published: (2011-12-01)

Exploring Selectivity of Multikinase Inhibitors across the Human Kinome
by: Filip Miljković, et al.
Published: (2018-01-01)

Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
by: Lin T, et al.
Published: (2017-04-01)

Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis
by: Yasuhiro Kondoh, et al.
Published: (2022-02-01)

Use of multikinase inhibitors/lenvatinib concomitant with antiresorptive therapy for bone metastases from radioiodine‐resistant differentiated thyroid cancer
by: Elena Navarro‐Gonzalez
Published: (2022-10-01)

Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors – a single Brazilian center experience
by: Natalia Treistman, et al.
Published: (2021-05-01)

Prescribing patterns and determinants for elderly patients with Parkinson's disease in Japan: a retrospective observational study using insurance claims databases
by: Morinobu Seki, et al.
Published: (2023-06-01)

Prescription of anti-influenza drugs in Japan, 2014-2020: A retrospective study using open data from the national claims database.
by: Akahito Sako, et al.
Published: (2023-01-01)

Incidence of Mumps Deafness in Japan, 2005–2017: Analysis of Japanese Insurance Claims Database
by: Akira Takagi, et al.
Published: (2022-01-01)

E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib
by: Nicola Bougen-Zhukov, et al.
Published: (2022-03-01)

Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension
by: Swathi Veeroju, et al.
Published: (2021-02-01)

Experience of Hepatocellular Cancer Therapy with Multikinase Inhibitors in the Republic of Bashkortostan
by: Sh. Kh. Gantsev, et al.
Published: (2020-11-01)

Clinically relevant drug interactions with multikinase inhibitors: a review
by: Koen G. A. M. Hussaarts, et al.
Published: (2019-01-01)

Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor
by: Anna Strasma, et al.
Published: (2021-03-01)